Press Releases

July 18, 2022

ROME Therapeutics Appoints Industry Veteran Jeff Hatfield as Chair of Board of Directors

June 30, 2022

ROME Therapeutics Announces Publication of First Crystal Structure of a Human Endogenous Reverse Transcriptase in PNAS

April 26, 2022

ROME Therapeutics Appoints Nurjana Bachman, Ph.D., as Senior Vice President, Corporate Development and Strategy

November 8, 2021

ROME Therapeutics Announces Preclinical Data Demonstrating Inhibition of Endogenous Reverse Transcriptase Activity Blocks Immune Response in Autoimmune Disease Models

Reveal more

In the news

September 22, 2022

ROME honored in Endpoints 11: The top private biotechs in pursuit of new drugs  |  Endpoints News

May 3, 2022

The Mysterious Dark Genome: Panel Featuring Rosana Kapeller, CEO of ROME  |  World Medical Innovation Forum

Reveal more

Publications and presentations

June 30, 2022

Human endogenous retrovirus-K (HERV-K) reverse transcriptase (RT) structure and biochemistry reveals remarkable similarities to HIV-1 RT and opportunities for HERV-K–specific inhibition  |  PNAS

June 5-9, 2022

Sensitive Detection of LINE-1 Retrotransposition Across Cancer Uncovers Biological Correlates | The Mobile DNA Conference: Evolution, Diversity, and Impact

Reveal more